

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/054286 A2

(51) International Patent Classification⁷: C07K 14/54,
14765

(21) International Application Number:
PCT/GB2004/005091

(22) International Filing Date: 3 December 2004 (03.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03027770.1 3 December 2003 (03.12.2003) EP

(71) Applicant (for all designated States except US): DELTA
BIOTECHNOLOGY LIMITED [GB/GB]; Castle Court,
59 Castle Boulevard, Nottingham NG7 1FD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KRÖZ, M.
[DE/DE]; ZLB Behring GmbH, P.O. Box 1230, D-35002
Marburg (DE). DICKNEITE, G. [DE/DE]; ZLB Behring
GmbH, P.O. Box 1230, D-35002 Marburg (DE). HAUSER,
Hans-Peter [DE/DE]; Feucrdomweg 6, D-35041 Marburg

(DE). WEIMER, T. [DE/DE]; ZLB Behring GmbH,
P.O. Box 1230, D-35002 Marburg (DE). SLEEP, Darrell
[GB/GB]; 66 Ladybay Road, West Bridgford, Nottingham
NG2 5DS (GB).


(74) Agent: BASSETT, Richard; Eric Potter Clarkson, Park
View House, 58 The Ropewalk, Nottingham NG1 5DD
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: INTERLEUKIN-11 FUSION PROTEINS



(57) Abstract: The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or antiinflammatory properties, fused to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as "albumin fusion proteins of the invention". These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.



FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*